Joseph P. Lyssikatos Sells 527 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 527 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total value of $14,513.58. Following the completion of the sale, the insider now owns 1,077,409 shares of the company’s stock, valued at $29,671,843.86. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Enliven Therapeutics Trading Up 7.9 %

ELVN opened at $27.53 on Friday. The business’s 50 day moving average is $23.21 and its 200-day moving average is $21.97. The stock has a market cap of $1.29 billion, a PE ratio of -14.26 and a beta of 1.09. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, analysts forecast that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Analysts Set New Price Targets

ELVN has been the topic of a number of research reports. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday. Finally, Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ELVN. Quest Partners LLC lifted its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after purchasing an additional 3,189 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter valued at $167,000. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter worth $256,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics in the second quarter valued at $322,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.